Format

Send to

Choose Destination
Curr Opin Urol. 2012 Jan;22(1):7-15. doi: 10.1097/MOU.0b013e32834d9bfd.

α-Blockers for benign prostatic hyperplasia: the new era.

Author information

1
Department of Urology, New York University School of Medicine, New York University, New York, New York, USA. herbert.lepor@nyumc.org

Abstract

PURPOSE OF REVIEW:

α1-Adrenoceptor blockers are the most frequently prescribed medical therapy in the treatment of lower urinary tract symptom suggestive of benign prostatic hyperplasia (LUTS/BPH). The purpose of this review is to highlight the evolution of adrenoceptor blockers with emphasis on newly approved drugs.

RECENT FINDINGS:

Over the past years new formulations of several α1-adrenoceptor blockers were introduced to the market. Five long-acting α1-blockers are currently approved by the Food and Drug Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, alfuzosin and silodosin. Silodosin is the only adrenoceptor blocker that exhibits true selectivity for the α1-adrenoceptor subtypes. This unique adrenoceptor selectivity profile likely accounts for the very favorable cardiovascular safety profile.

SUMMARY:

Tamsulosin, alfuzosin slow release and silodosin do not require dose titration. Alfuzosin, terazosin, doxazosin and silodosin have all been shown to be effective in relieving LUTS/BPH independent of prostate size. Low incidence of orthostatic hypotension has been reported for silodosin, but abnormal ejaculation is the most commonly reported adverse effect.

PMID:
22080875
DOI:
10.1097/MOU.0b013e32834d9bfd
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center